Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bret Lashner

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Inflammatory Bowel Diseases|February 2, 2012
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseLior Katz, Javier P Gisbert, Beth Manoogian, et al.
Pageof 6